On the onset, everything looks bad about this company except PRICE ACTION & FY23 AR (Especially Director's Report)
Some Key factors in the report
- Strategy of moving business to focussed subsidiaries has been successful - Asence Pharma has started a new Oncology and Synthetic API plant - Synbiotics is manufacturing an antifungal active ingredient - Amphotericin B - Sarabhai M Chemicals has started manufacturing Vitamin C coated products - Vovantis Labs has setup a state of art manufacturing facility to expand business - CoSara DIagnostics has the exclusive manufacturing rights in India for the complete menu of its US partner - Co-Diagnostics
So many turnaround factors which is clearly indicated by Price Action
Technicals
On a monthly chart, PA has formed a CUP and HANDLE with breakout. This is a powerful indication of confirming the fundamentals stated above.
This pick is for those who like turnaround candidates (dark horse)
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.